Siberian-made EpiVacCorona Covid-19 vaccine creates antibodies in 100% of participants in initial small-scale trial

All volunteers vaccinated

All volunteers vaccinated by Siberia’s Vector Research Center’s EpiVacCorona coronavirus formula have developed antibodies. The vaccine has completed its first two phases of testing, involving just 100 people.

While a vaccine needs thousands of people to be tested before its quality is proven, the latest news is an optimistic sign for the future.

Continue reading